Advancing Tuberculosis Chemotherapy: Targeted Nanomedicines for the Mycobacterium TB Granuloma
Small · 2025-12 · 21 (49)
DOI: 10.1002/smll.202506381 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Small, online erschienen am 30.10.2025. Verfasst von Shreya Ranjith Singh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Scienc…. Hauptthemen laut MEDLINE: Granuloma, Nanomedicine, Tuberculosis, Mycobacterium tuberculosis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 193 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation.
Themen: Onkologische Pflege
Abstract (Originalsprache)
This review examines the potential of nanosystems for targeted tuberculosis (TB) therapy, focusing on biodegradable polymeric, lipid‐based, extracellular vesicles, and selected inorganic nanocarriers engineered to deliver anti‐TB drugs directly to granulomas, the hallmark of TB pathology. Both passive and active targeting strategies are discussed, emphasizing how these approaches enhance drug accumulation at infection sites to curb disease progression. Preclinical studies, including laboratory and animal models, are reviewed to assess their therapeutic impact. Although the results are promising, hurdles such as biocompatibility, regulatory constraints, and optimizing drug release still pose challenges for clinical implementation. However, rationally designed nanosystems hold significant potential for improving TB treatment outcomes. Further research is crucial for refining nanocarrier design and addressing translational hurdles. Future directions include integrating nanosystems with advanced molecular imprinting technologies (MIT) and molecularly imprinted polymer nanoparticles (MIPNPs) for enhanced granuloma targeting and controlled drug release. Additionally, immunotherapy and gene therapy offer novel adjunct strategies to boost host immunity and deliver targeted genetic interventions. These emerging approaches, combined with optimized nanosystems, have the potential to revolutionize TB management by improving drug delivery, reducing treatment duration, and enhancing therapeutic outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, 7 York Road Parktown, Johannesbur…
- Molecular Sciences Institute, School of Chemistry, University of the Witwatersrand, Private Bag 3, PO WITS, 2050, South Africa.
- Wits Infectious Diseases and Oncology Research Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
ORCID-Profile: Shreya Ranjith Singh, Maya Mellisa Makatini, Thashree Marimuthu, Yahya Essop Choonara
Förderung
- National Research Foundation
Zitieren
APA
Ranjith Singh, S., Makatini, M. M., Marimuthu, T., & Choonara, Y. E. (2025). Advancing Tuberculosis Chemotherapy: Targeted Nanomedicines for the Mycobacterium TB Granuloma. Small, 21(49). https://doi.org/10.1002/smll.202506381
Vancouver
Ranjith Singh S, Makatini MM, Marimuthu T, Choonara YE. Advancing Tuberculosis Chemotherapy: Targeted Nanomedicines for the Mycobacterium TB Granuloma. Small. 2025;21(49). doi:10.1002/smll.202506381
BibTeX
@article{RanjithSingh2025,
author = {Ranjith Singh, Shreya and Makatini, Maya Mellisa and Marimuthu, Thashree and Choonara, Yahya Essop},
title = {Advancing Tuberculosis Chemotherapy: Targeted Nanomedicines for the Mycobacterium TB Granuloma},
journal = {Small},
year = {2025},
volume = {21},
number = {49},
doi = {10.1002/smll.202506381}
}
EUVIMED